Erbitux utilization (correction)
Executive Summary
First-line colorectal cancer penetration for Bristol-Myers Squibb/ImClone's Erbitux (cetuximab) was 4% in the fourth quarter of 2005. Second- and third-line penetration was 13% and 31%, respectively, ImClone said. Among the total number of patients using Erbitux, 82% were being treated for colorectal cancer. In a Jan. 30 story, "The Pink Sheet" (p. 14) incorrectly characterized Erbitux usage in the overall colorectal cancer population...